CATALOGO DEI PRODOTTI DELLA RICERCA

GAJOFATTO, Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.501
NA - Nord America 6.891
AS - Asia 4.416
SA - Sud America 591
AF - Africa 173
OC - Oceania 31
Continente sconosciuto - Info sul continente non disponibili 10
Totale 19.613
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.765
RU - Federazione Russa 2.817
CN - Cina 1.647
SG - Singapore 1.621
IT - Italia 1.304
GB - Regno Unito 1.234
BR - Brasile 492
SE - Svezia 446
FR - Francia 377
HK - Hong Kong 371
DE - Germania 335
IE - Irlanda 303
FI - Finlandia 283
VN - Vietnam 270
KR - Corea 96
CA - Canada 75
IN - India 75
NL - Olanda 73
EG - Egitto 65
UA - Ucraina 65
TR - Turchia 50
JP - Giappone 49
ID - Indonesia 44
BE - Belgio 43
PL - Polonia 41
ES - Italia 36
AR - Argentina 35
ZA - Sudafrica 34
AT - Austria 32
IR - Iran 32
MX - Messico 29
PK - Pakistan 29
AU - Australia 28
BD - Bangladesh 24
CH - Svizzera 22
CZ - Repubblica Ceca 19
CL - Cile 16
EC - Ecuador 16
IQ - Iraq 15
BJ - Benin 13
JO - Giordania 12
TG - Togo 12
IL - Israele 11
MA - Marocco 11
MK - Macedonia 11
GR - Grecia 10
PY - Paraguay 10
UZ - Uzbekistan 10
SA - Arabia Saudita 9
AE - Emirati Arabi Uniti 7
CO - Colombia 7
EU - Europa 7
VE - Venezuela 7
DK - Danimarca 6
KE - Kenya 6
LV - Lettonia 6
NO - Norvegia 6
OM - Oman 6
DO - Repubblica Dominicana 5
HU - Ungheria 5
LT - Lituania 5
RO - Romania 5
SD - Sudan 5
TN - Tunisia 5
AZ - Azerbaigian 4
CI - Costa d'Avorio 4
JM - Giamaica 4
NP - Nepal 4
PA - Panama 4
PE - Perù 4
AL - Albania 3
AM - Armenia 3
CR - Costa Rica 3
CY - Cipro 3
DZ - Algeria 3
NG - Nigeria 3
NZ - Nuova Zelanda 3
PH - Filippine 3
PT - Portogallo 3
SN - Senegal 3
TH - Thailandia 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BO - Bolivia 2
CG - Congo 2
GE - Georgia 2
KG - Kirghizistan 2
KH - Cambogia 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LU - Lussemburgo 2
ML - Mali 2
MN - Mongolia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AD - Andorra 1
BB - Barbados 1
Totale 19.599
Salva come PNG Salva come JPEG
Città #
Dallas 1.060
Moscow 994
Southend 987
Chandler 786
Ashburn 748
Singapore 735
Woodbridge 382
Ann Arbor 374
Hong Kong 361
Jacksonville 331
Beijing 314
Dublin 304
Verona 222
New York 206
Houston 161
The Dalles 135
Los Angeles 127
Wilmington 126
Lawrence 122
Princeton 122
Jinan 110
Helsinki 106
Nanjing 103
Milan 93
Hebei 88
Shenyang 88
Munich 76
Boardman 72
Ho Chi Minh City 67
Columbus 61
Redondo Beach 61
Buffalo 60
Washington 57
Santa Clara 52
São Paulo 52
Tianjin 51
Hanoi 47
Zhengzhou 46
Rome 45
Changsha 44
Lancaster 44
Brussels 43
Council Bluffs 43
Dong Ket 43
Redwood City 42
Ningbo 40
Turku 40
Hangzhou 38
Tokyo 38
Haikou 37
Nanchang 37
Jakarta 35
London 35
Redmond 35
Warsaw 35
Guangzhou 32
Cairo 31
Montreal 31
Seattle 31
Bologna 30
Taiyuan 30
Johannesburg 28
Sindelfingen 28
Taizhou 28
Seoul 27
Atlanta 23
Amsterdam 22
Boston 22
Stockholm 22
Brooklyn 21
Denver 21
Fuzhou 21
Naples 21
Dearborn 20
Falls Church 20
Istanbul 20
Orem 20
Tehran 20
Chicago 19
Jiaxing 19
Phoenix 19
Chennai 18
Norwalk 18
Nuremberg 18
Padova 18
Shanghai 18
Catania 17
Poplar 17
Belo Horizonte 15
Olomouc 15
Vienna 15
Frankfurt am Main 14
Lanzhou 14
San Francisco 14
Clearwater 13
Cotonou 13
Mexico City 13
Amman 12
Florence 12
Lappeenranta 12
Totale 11.473
Salva come PNG Salva come JPEG
Nome #
Tolebrutinib. Bruton tyrosine kinase (BTK) inhibitor Treatment of multiple sclerosis 574
Psicologia positiva e disabilità: affrontare le sfide del futuro nell'adulto con disabilità acquisita, cronica e progressiva 420
Analisi delle alterazioni funzionali dell’arto superiore e dell’attività muscolare mediante emgs in pazienti con sclerosi multipla: uno studio “cross-sectional” 288
The effectiveness of combining a home-based Digital motor Telerehabilitation program with conventional therapy in progressive multiple sclerosis: A study protocol for a multicenter, randomized controlled trial 285
Biopsychosocial model of resilience in young adults with multiple sclerosis (BPS-ARMS): an observational study protocol exploring psychological reactions early after diagnosis 266
A bio-psycho-social co-created intervention for young adults with multiple sclerosis (ESPRIMO): rationale and study protocol for a feasibility study 249
Gestione degli eventi avversi dei farmaci modificanti il decorso della malattia nella sclerosi multipla 240
Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study 225
A randomized controlled trial of IV immunoglobulin in patients with postpolio syndrome. 221
Two sisters with Leukoencephalopathy, hearing loss and retinopathy: a familial case of Susac's Syndrome? 207
Un caso di sclerosi multipla con esordio "tumor-like" e decorso benigno 206
A Case-control study of myelin oligodendrocyte glycoprotein and CD45 polymorphisms in multiple sclerosis in Verona, Italy 202
Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders 201
Antibody response against HERV-W env surface peptides differentiates multiple sclerosis and neuromyelitis optica spectrum disorder 200
Levofloxacin-induced hemichorea-hemiballism in a patient with previous thalamic infarction 199
Insights for fostering resilience in young adults with multiple sclerosis in the aftermath of the COVID-19 emergency: an Italian survey 196
Prevalence of multiple sclerosis in Verona, Italy: an epidemiologic and genetic study 195
Clinical and biomarker assessment of demyelinating events suggesting multiple sclerosis. 192
Can the degree of meningeal inflammation and cortical pathology be used to stratify early progressive MS patients? 191
QTc interval in patients with multiple sclerosis: an inference from the insula of Reil? 191
An active case of radiologically isolated syndrome: from MRI detection to multiple sclerosis 188
Cognitive onset in multiple sclerosis 188
Brentuximab vedotin: axonal microtubule's Apollyon 188
A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band 187
A case of acute fulminant multiple sclerosis treated with alemtuzumab 185
Risk factors for post-polio syndrome among an Italian population: a case-control study. 184
A case of multifocal CIS with unusual MRI features suggestive of Balo's concentric sclerosis 184
EFFETTI DI UN TRAINING DI INTEGRAZIONE SENSORI – MOTORIA SUI DISTURBI DELL’EQUILIBRIO IN PAZIENTI CON SCLEROSI MULTIPLA: UNO STUDIO RANDOMIZZATO CONTROLLATO 184
Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients? 183
GLI EFFETTI DI DUE DIVERSI TIPI DI TRATTAMENTO MOTORIO SULLE FUNZIONI COGNITIVE IN PAZIENTI CON SCLEROSI MULTIPLA 183
Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases 183
“If You Can’t Control the Wind, Adjust Your Sail”: Tips for Post-Pandemic Benefit Finding from Young Adults Living with Multiple Sclerosis. A Qualitative Study 183
Intravenous immunoglobulin for post-polio syndrome: a randomized double-blind, placebo-controlled study 180
A panel of exploratory CSF biomarkers in patients with an initial demyelinating event of the CNS: does it add relevant information to usual work-up? 172
Assessment of outcome predictors in first-episode acute myelitis: a retrospective study of 53 cases. 171
2017 McDonald criteria for multiple sclerosis: Earlier diagnosis with reduced specificity? 171
e-ESPRIMO: An e-health biopsychosocial intervention for young adults with Multiple sclerosis and medium/high disability. Co-creation phase 168
A case of multiple sclerosis and necrotizing autoimmune myopathy with anti-SRP antibodies 167
High-intensity robot-assisted hand training in individuals with multiple sclerosis: a randomized, controlled, single-blinded trial 167
Characterization of Upper Limb Impairments at Body Function, Activity, and Participation in Persons With Multiple Sclerosis by Behavioral and EMG Assessment: A Cross-Sectional Study 165
An exploratory panel of cerebrospinal fluid biomarkers compared to standard diagnostic evaluation in initial demyelinating events suggestive of multiple sclerosis 164
Amyloid myopathy: an intriguing diagnosis 161
Correlation between cerebrospinal fluid markers of neurodegeneration and MRI measures of gray matter pathology in multiple sclerosis 159
Benign course of tumour-like multiple sclerosis. Report of five cases and literature review. 158
Late-onset multiple sclerosis presenting with cognitive dysfunction and severe cortical/infratentorial atrophy. 158
Prevalence of multiple sclerosis in Verona, Italy: an epidemiological and genetic study. 156
Response to Nagai et al. 156
Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study. 155
Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD 155
Regional distribution and evolution of grey matter changes in different MS phenotypes: a 5-year longitudinal study 154
Benign multiple sclerosis: physical and cognitive impairment follow distinct evolutions 154
A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study 153
Epilepsy in multiple sclerosis: The role of temporal lobe damage 153
Acute cardiovascular dysfunction in multiple sclerosis: report of two cases and literature review 152
Physical disability and cognitive impairment evolution in benign multiple sclerosis: a five years prospective study 149
Increased cortical lesion load and intrathecal inflammation is associated with oligoclonal bands in multiple sclerosis patients: a combined CSF and MRI study 149
HPV-related papillary squamous cell carcinoma of the tonsil during treatment with fingolimod 149
Effects of high-intensity robot-assisted training in hand function recovery and adl independence in individuals with multiple sclerosis: A randomized controlled single-blinded trial 146
Increase of CSF inflammatory profile in a case of highly active multiple sclerosis 145
Up-regulated serum miR-128-3p in progressive and relapse-free multiple sclerosis patients 144
EFFECTIVENESS OF A SENSORIMOTOR INTEGRATION TRAINING ON BALANCE DISORDERS IN PATIENTS WITH MULTIPLE SCLEROSIS: A RANDOMIZED CONTROLLED TRIAL 143
Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis 142
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 141
Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study 140
Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis 139
The diagnosis of multiple sclerosis: pinpointing the concept of "no better explanation" 135
Sensory integration balance training in patients with multiple sclerosis: A randomized, controlled trial 133
Increased cerebrospinal fluid cystatin C may predict disability after acute myelitis 132
Effects of high-intensity robot-assisted hand training on upper limb recovery and muscle activity in individuals with multiple sclerosis: a randomized, controlled, single-blinded trial 132
Evaluating upper upper limb dysfunctions in patients with multiple sclerosis: an electromyography cross sectional study 132
Cerebrospinal fluid markers in sporadic Creutzfeldt-Jakob disease. 130
Long-term clinical, cognitive and MRI characteristics of patients with untreated benign multiple sclerosis: a natural history study 130
Mycobacterium avium subspecies paratuberculosis and myelin basic protein specific epitopes are highly recognized by sera from patients with Neuromyelitis optica spectrum disorder 130
Clinical and demographic predictors of response to first-line therapies in relapsing-remitting multiple sclerosis 129
Regional distribution and evolution of gray matter damage in different populations of multiple sclerosis patients 129
HCV-related nervous system disorders. 128
"Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study 128
Two sisters with leukoencephalopathy, hearing loss and retinopathy: a familial case of Susac's syndrome? 127
Inflammatory intrathecal profiles and cortical damage in multiple sclerosis 126
Increased cortical lesion load and CSF cytokines in oligoclonal band positive MS patients 125
Prognostic value of multimodal evoked potentials in multiple sclerosis: the EP score. 124
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study) 124
Physicochemical properties of Aβ peptides in cerebrospinal fluid of Alzheimer’s disease patients 121
Diagnostic features of initial demyelinating events associated with serum MOG-IgG 120
Promoting participatory research in chronicity: The ESPRIMO biopsychosocial intervention for young adults with multiple sclerosis 118
Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015 118
Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis 118
Changing therapeutic strategies and persistence to disease-modifying treatments in a population of multiple sclerosis patients from Veneto region, Italy 117
A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia 117
Long survival and clinical stability in Marburg's variant multiple sclerosis. 116
Long lesions on initial spinal cord MRI predict a final diagnosis of acute disseminated encephalomyelitis versus multiple sclerosis in children 113
Ofatumumab for relapsing forms of multiple sclerosis 112
Resting-state functional connectivity in multiple sclerosis patients receiving nabiximols for spasticity 110
Prognostic factors of acute partial transverse myelitis. 110
Clinical, MRI, and CSF markers of disability progression in multiple sclerosis 110
Study protocol on advance care planning in multiple sclerosis (ConCure-SM): intervention construction and multicentre feasibility trial 110
Early predictors of recovery, symptom recurrence, conversion to multiple sclerosis and long-term disability after acute myelitis 109
Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD 108
A Panel of Exploratory CSF Biomarkers in Patients with an Initial Demyelinating Event of the CNS: Does It Add Relevant Information to Usual Work-Up? (P02.080) 103
Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. 103
Totale 16.531
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.089
article - articoli 60.327
book - libri 0
conference - conferenze 2.117
curatela - curatele 0
other - altro 448
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.197
Totale 128.178
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021472 0 0 0 0 0 103 28 41 65 35 104 96
2021/20221.177 98 418 31 123 27 23 11 74 36 32 74 230
2022/20232.274 153 291 212 372 175 483 30 142 246 30 88 52
2023/20241.867 65 114 181 157 241 402 92 154 20 107 178 156
2024/20253.312 169 200 201 486 174 148 188 178 478 246 274 570
2025/20266.765 680 484 1.092 1.534 2.521 454 0 0 0 0 0 0
Totale 19.838